How The BeOne Medicines (ONC) Story Is Shifting With Sonrotoclax And Brukinsa

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

The latest analyst update on BeOne Medicines fine tunes the model fair value estimate from US$408.32 to US$411.51 per share, reflecting incremental shifts in long term assumptions. Recent commentary links this change to how the first FDA accelerated approval for sonrotoclax and the evolving outlook for Brukinsa contribute to differing views on growth durability and execution risk. As you read on, you will see how these moving pieces shape the evolving narrative and what to watch to stay on top of it.

Stay updated as the Fair Value for BeOne Medicines shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on BeOne Medicines.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Leerink raised its price target to US$367 after the FDA granted accelerated approval for sonrotoclax in relapsed or refractory mantle cell lymphoma, highlighting sonrotoclax as an emerging contributor alongside Brukinsa. Truist increased its price target to US$412 and pointed to the company outlook suggesting healthy Brukinsa growth even without major label expansion, which supports more confident long term revenue assumptions. RBC Capital lifted its price target to US$425 and noted that previously feared competition has left Brukinsa revenues largely unimpacted in recent periods, supporting the view that the core hematology franchise remains resilient. Barclays moved its target to US$405 and pointed to upcoming 2026 data disclosures as a potential source of longer term pipeline contribution beyond Brukinsa.

🐻 Bearish Takeaways

Jefferies cut its price target to US$290 from US$420 and moved to a Hold rating, arguing that while Brukinsa is one of the stronger hematology assets, the stock does not appear mispriced at current levels and that the next growth drivers are slower to develop.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NasdaqGS:ONC 1-Year Stock Price Chart

See how BeOne Medicines' fair value stacks up across multiple valuation models — not just analyst targets.

What's in the News

The U.S. FDA granted accelerated approval to BEQALZI (sonrotoclax) for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies, supported by Phase 1/2 BGB-11417-201 data and multiple expedited designations. Sonrotoclax is being studied in the confirmatory CELESTIAL-RRMCL trial, already holds approvals in China for certain lymphoma indications, and is part of a global program with more than 2,200 patients, including combination studies with zanubrutinib. The U.S. FDA granted Priority Review to a supplemental Biologics License Application for TEVIMBRA (tislelizumab) plus ZIIHERA (zanidatamab) and chemotherapy in first-line HER2-positive gastric and related cancers, based on interim Phase 3 HERIZON-GEA-01 results. BeOne updated 2026 guidance and now expects total revenue of US$6.3b to US$6.5b and GAAP operating income of US$750m to US$850m, compared with prior guidance of US$6.2b to US$6.4b and GAAP operating income of US$700m to US$800m.

Story Continues

How This Changes the Fair Value For BeOne Medicines

Fair value estimate adjusted from US$408.32 to US$411.51 per share. Projected long term revenue growth rate updated from 15.33% to 14.26%. Assumed net profit margin revised from 17.20% to 19.19%. Target future P/E multiple reset from 42.49x to 34.98x. Discount rate assumption moved from 6.93% to 6.99%.

Never Miss an Update: Follow The Narrative

Narratives connect BeOne Medicines' business story with analysts' forecasts and fair value, updating as new clinical, regulatory, and financial data comes through. They help you see how individual news items fit into a bigger picture rather than in isolation.

Head over to the Simply Wall St Community and follow the Narrative on BeOne Medicines to stay up to date on:

How the BRUKINSA centered hematology franchise, backed by guidance in the US$5.0b to US$5.3b range and broad international approvals, fits into a bigger revenue and margin story. The role of sonrotoclax, BTK CDAC, TEVIMBRA and other late stage assets, with over 20 Phase III trials and more than 10 proof of concept readouts expected by 2026, in shaping future earnings potential. The key risks around heavy reliance on a narrow product base, rising competition in BTK and protein degradation therapies, regulatory pricing pressure, and execution and supply chain challenges across a growing global pipeline.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ONC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments